Therefore, a strict time window is set up (4.5 hours) for thrombolytic treatment.73 Recently, it has been found that delayed recombinant tissue plasminogen activator (rtPA) treatment after ischemic stroke increased inflammasome activation in microglia thus increasing the risk of HT after ischemic stroke, which sheds light on the conclusion that inflammasome activation is the key limitation for therapeutic window for rtPA.74 Inhibiting inflammasome activation has displayed preventive efficacy for HT in ischemic stroke. The gene discussed is PLAT; the disease is ischemic stroke.